<DOC>
	<DOCNO>NCT01159743</DOCNO>
	<brief_summary>The purpose study compare body fat distribution Human Immunodeficiency Virus-1 ( HIV-1 ) infect patient receive , since begin least two year , antiretroviral therapy base efavirenz lopinavir/ritonavir combination tenofovir plus emtricitabine ( lamivudine ) .</brief_summary>
	<brief_title>A Comparison Body Fat Distribution HIV-1 Infected Patients Receiving , Since Beginning Least Two Years , Antiretroviral Therapy Based Efavirenz Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine Lamivudine</brief_title>
	<detailed_description>Lipodystrophy ( also call abnormal fat redistribution ) associate HIV infection characterize loss subcutaneous adipose tissue ( lipoatrophy ) apparent limb , face , buttock , accumulation adipose tissue ( lipohypertrophy ) intra-abdominal cavity , mid , upper back , breast . Lipodystrophy may also occur mixed form ( lipoatrophy lipohypertrophy patient ) . Participants make single study visit . Dual energy X-ray absorptiometry ( DEXA ) perform within 30 day study visit . In addition , routine visit clinical result , demographic data , disease data , comorbidities concomitant medication collect .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Inclusion Criteria Men woman age â‰¥ 18 year HIV1 infection clinically stable invited participate study routine followup visit . HIV1 infect patient receive since begin continuously , least two year , initial antiretroviral therapy ( ART ) base efavirenz ( EFV ) combination tenofovir ( TDF ) + emtricitabine ( FTC ) [ lamivudine ( 3TC ) ] HIV1 infect patient receive since begin continuously , least two year , initial ART base lopinavir/ritonavir ( LPV/r ) combination TDF +FTC ( 3TC ) . Patients undetectable viral load , response detection limit participate hospital define last 6 month . Patients give write informed consent participate study [ personal data collection performance dual energy Xray absorptiometry ( DEXA ) ] . Exclusion Criteria Patients receive point efavirenz ( EFV ) lopinavir/ritonavir ( LPV/r ) combination regimen thereafter . Patients structure treatment interruption ( therapeutic holiday ) . Patients body mass index &lt; 16 kg/m^2 . Patients metallic prosthesis prosthetic material could interfere measurement dual energy Xray absorptiometry ( DEXA ) . Patients history plastic repair surgery buttocks breast . Patients diagnostic test barium radionucleotides , perform last month . Pregnant woman . Patients treat agent investigational phase . Patients current treatment systemic corticosteroid chemotherapy . Diabetes mellitus hypoglycaemic treatment . Transsexualism ( though implicit prosthesis drug ) . Any drug take chronically , may alter distribution fat adipocyte biology ( insulin , nonsteroidal antiinflammatory drug , etc ) . Patient undergone liposuction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>lipodystrophy</keyword>
	<keyword>Lipoatrophy</keyword>
	<keyword>antiretroviral treatment</keyword>
</DOC>